{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:34:34Z","timestamp":1779921274552,"version":"3.53.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01518-8","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T13:14:07Z","timestamp":1755350047000},"page":"2997-3007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of 5-Fluorouracil 4% Cream in the Treatment of Hyperkeratotic Actinic Keratosis: A Single-Center Retrospective Real-World Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Federica","family":"Li Pomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"d\u2019Aloja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Rottura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Irrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-8441","authenticated-orcid":false,"given":"Francesco","family":"Borgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"6","key":"1518_CR1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/jdv.19897","volume":"38","author":"L Kandolf","year":"2024","unstructured":"Kandolf L, Peris K, Malvehy J, et al. European consensus based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV induced dysplasia and field cancerization\u2014on behalf of the European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology, and Union of Medical Specialists. J Eur Acad Dermatol Venereol. 2024;38(6):1024\u201347. https:\/\/doi.org\/10.1111\/jdv.19897.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1 Suppl","key":"1518_CR2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1067\/mjd.2000.103339","volume":"42","author":"RG Glogau","year":"2000","unstructured":"Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1 Suppl):S23-4. https:\/\/doi.org\/10.1067\/mjd.2000.103339.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1518_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/0190-9622(91)70113-G","volume":"24","author":"EA Olsen","year":"1991","unstructured":"Olsen EA, Abernethy ML, Kulp Shorten C, et al. A double blind, vehicle controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24(5):738\u201343. https:\/\/doi.org\/10.1016\/0190-9622(91)70113-G.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1518_CR4","first-page":"1218","volume":"15","author":"MA Dohil","year":"2016","unstructured":"Dohil MA. Efficacy, safety, and tolerability of 4 % 5-fluorouracil cream in a novel aqueous cream containing peanut oil once daily compared with 5 % 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis. J Drugs Dermatol. 2016;15(10):1218\u201324.","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 3","key":"1518_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.07860.x","volume":"156","author":"J R\u00f6wert-Huber","year":"2007","unstructured":"R\u00f6wert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl 3):8\u201312. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07860.x.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1518_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/jdv.13626","volume":"30","author":"L Schmitz","year":"2016","unstructured":"Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30(8):1303\u20137. https:\/\/doi.org\/10.1111\/jdv.13626.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"1518_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jdv.14092","volume":"31","author":"E Stockfleth","year":"2017","unstructured":"Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31(Suppl 2):8\u201311. https:\/\/doi.org\/10.1111\/jdv.14092.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1518_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2021.100661","volume":"96","author":"E Stockfleth","year":"2022","unstructured":"Stockfleth E, B\u00e9geault N, Delarue A. The overall number of actinic keratosis lesions is not predictable by the number of visible lesions: consequences for field directed therapies. Curr Ther Res Clin Exp. 2022;96:100661.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1518_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40266-022-00919-0","volume":"39","author":"P Calzavara Pinton","year":"2022","unstructured":"Calzavara Pinton P, Calzavara Pinton I, Rovati C, Rossi M. Topical pharmacotherapy for actinic keratoses in older adults. Drugs Aging. 2022;39(2):143\u201352. https:\/\/doi.org\/10.1007\/s40266-022-00919-0.","journal-title":"Drugs Aging"},{"issue":"4","key":"1518_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ijd.14147","volume":"58","author":"ECV de Oliveira","year":"2019","unstructured":"de Oliveira ECV, da Motta VRV, Pantoja PC, et al. Actinic keratosis\u2014review for clinical practice. Int J Dermatol. 2019;58(4):400\u20137. https:\/\/doi.org\/10.1111\/ijd.14147.","journal-title":"Int J Dermatol"},{"issue":"9","key":"1518_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","volume":"151","author":"H Pomerantz","year":"2015","unstructured":"Pomerantz H, Hogan D, Eilers D, et al. Long term efficacy of topical fluorouracil cream, 5 %, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015;151(9):952\u201360. https:\/\/doi.org\/10.1001\/jamadermatol.2015.0502.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1518_CR12","doi-asserted-by":"publisher","first-page":"e2023151","DOI":"10.5826\/dpc.1302a151","volume":"13","author":"G Briatico","year":"2023","unstructured":"Briatico G, Brancaccio G, Scharf C, et al. Real world experience with topical 5-fluorouracil 4 % (40\u00a0mg\/g) cream for the treatment of actinic keratosis. Dermatol Pract Concept. 2023;13(2):e2023151. https:\/\/doi.org\/10.5826\/dpc.1302a151.","journal-title":"Dermatol Pract Concept"},{"key":"1518_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17845","author":"F Li Pomi","year":"2025","unstructured":"Li Pomi F, d\u2019aloja A, Rottura M, Vaccaro M, Borgia F. Tirbanibulin 1 % ointment for the treatment of hyperkeratotic actinic keratosis. J Dermatol. 2025. https:\/\/doi.org\/10.1111\/1346-8138.17845.","journal-title":"J Dermatol"},{"key":"1518_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2025.104555","volume":"53","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Luan J, Tang Y, Ma W, Wu W, Chen S. Efficacy of 5-aminolevulinic acid photodynamic therapy for Olsen grade 3 actinic keratosis: a prospective cohort study. Photodiagnosis Photodyn Ther. 2025;53:104555. https:\/\/doi.org\/10.1016\/j.pdpdt.2025.104555.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"5","key":"1518_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/jdv.12702","volume":"29","author":"JC Simon","year":"2015","unstructured":"Simon JC, Dominicus R, Karl L, et al. A prospective randomized exploratory study comparing once daily topical 0.5 % 5-fluorouracil with 10 % salicylic acid versus cryosurgery for hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29(5):881\u20139. https:\/\/doi.org\/10.1111\/jdv.12702.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1518_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13555-024-01336-4","volume":"15","author":"MV Heppt","year":"2025","unstructured":"Heppt MV, Trin K, Mille AC, Groc M, Delarue A, B\u00e9geault N. Association between local skin reactions and efficacy with 5-fluorouracil 4 % cream in actinic keratosis: post hoc analysis of two randomized clinical trials. Dermatol Ther. 2025;15(2):307\u201321. https:\/\/doi.org\/10.1007\/s13555-024-01336-4.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1518_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s13555-021-00668-9","volume":"12","author":"E Stockfleth","year":"2022","unstructured":"Stockfleth E, B\u00e9geault N, Delarue A. Intensity of local skin reactions during 5-fluorouracil treatment related to actinic keratosis lesion count: post hoc exploratory analysis. Dermatol Ther. 2022;12(2):467\u201379. https:\/\/doi.org\/10.1007\/s13555-021-00668-9.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1518_CR18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s13555-023-00902-6","volume":"13","author":"E Stockfleth","year":"2023","unstructured":"Stockfleth E, Jouary T, Farnetani F, et al. Severity of local skin reactions with 4% 5-fluorouracil plus emollient versus 4% 5-fluorouracil alone in actinic keratosis: single blind randomized trial. Dermatol Ther. 2023;13(4):1013\u201327. https:\/\/doi.org\/10.1007\/s13555-023-00902-6.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01518-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:05:46Z","timestamp":1758719146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01518-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01518-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Federica Li Pomi, Andrea d\u2019Aloja, Marta Vitale, Michelangelo Rottura, Natasha Irrera, Mario Vaccaro, and Francesco Borgia have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The procedures followed here were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. We have not used patients\u2019 names, initials, or hospital numbers. All patients had previously provided written informed consent for the use of their anonymized clinical data and to publish images, following institutional and ethical guidelines. The study was approved by the local ethical committee (protocol number 8\u201324 of May\u00a09, 2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}